Louis Lind Plesner1, Morten Dalsgaard1, Morten Schou1, Lars Køber2, Jørgen Vestbo3, Erik Kjøller1, Kasper Iversen1. 1. Department of Cardiology, Herlev Hospital, Copenhagen University Hospital, Denmark. 2. Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Denmark. 3. Centre for Respiratory Medicine and Allergy, Manchester Academic Health Science Centre, University Hospital South Manchester NHS Foundation Trust and the University of Manchester, England, United Kingdom.
Abstract
BACKGROUND: This study investigated the impact on all-cause mortality of airflow limitation indicative of chronic obstructive pulmonary disease or restrictive spirometry pattern (RSP) in a stable systolic heart failure population. HYPOTHESIS: Decreased lung function indicates poor survival in heart failure. METHODS: Inclusion criteria: NYHA class II-IV and left ventricular ejection fraction (LVEF) < 45%. Prognosis was assessed with multivariate Cox proportional hazards models. Two criteria of obstructive airflow limitation were applied: FEV1 /FVC < 0.7 (GOLD), and FEV1 /FVC < lower limit of normality (LLN). RSP was defined as FEV1 /FVC > 0.7 and FVC<80% or FEV1 /FVC > LLN and FVC <LLN. RESULTS: There where 573 patients in the cohort (85% of eligible patients in study period). Median follow-up was 4.7 years and 176 patients died (31%). Age, NYHA class, smoking, body mass index and LVEF were independent prognostic factors (p<0.01). Obstructive airflow limitation increased mortality using both criteria (HRGOLD 2.07 [95% CI 1.45-2.95] p<0.01 and HRLLN 2.00 [1.40-2.84] p<0.01) and was an independent marker when using LLN criteria (HR 1.74 [1.17-2.59] p=0.006). RSP was independently associated with mortality when defined as FVC < LLN (HR 1.54 [1.01-2.35] p=0.04) but not as FVC < 80%. Multivariate hazard ratios for a 10% decrease in predicted value of FEV1 or FVC were 1.42 (p<0.001) and 1.33 (p<0.001) in patients exhibiting airflow obstruction, and 1.36 (p=0.031) and 1.38 (p=0.041) in RSP. CONCLUSIONS: Presence of obstructive airflow limitation indicative of COPD or RSP were associated with increased all-cause mortality, however only independently when using the LLN definition.
BACKGROUND: This study investigated the impact on all-cause mortality of airflow limitation indicative of chronic obstructive pulmonary disease or restrictive spirometry pattern (RSP) in a stable systolic heart failure population. HYPOTHESIS: Decreased lung function indicates poor survival in heart failure. METHODS: Inclusion criteria: NYHA class II-IV and left ventricular ejection fraction (LVEF) < 45%. Prognosis was assessed with multivariate Cox proportional hazards models. Two criteria of obstructive airflow limitation were applied: FEV1 /FVC < 0.7 (GOLD), and FEV1 /FVC < lower limit of normality (LLN). RSP was defined as FEV1 /FVC > 0.7 and FVC<80% or FEV1 /FVC > LLN and FVC <LLN. RESULTS: There where 573 patients in the cohort (85% of eligible patients in study period). Median follow-up was 4.7 years and 176 patients died (31%). Age, NYHA class, smoking, body mass index and LVEF were independent prognostic factors (p<0.01). Obstructive airflow limitation increased mortality using both criteria (HRGOLD 2.07 [95% CI 1.45-2.95] p<0.01 and HRLLN 2.00 [1.40-2.84] p<0.01) and was an independent marker when using LLN criteria (HR 1.74 [1.17-2.59] p=0.006). RSP was independently associated with mortality when defined as FVC < LLN (HR 1.54 [1.01-2.35] p=0.04) but not as FVC < 80%. Multivariate hazard ratios for a 10% decrease in predicted value of FEV1 or FVC were 1.42 (p<0.001) and 1.33 (p<0.001) in patients exhibiting airflow obstruction, and 1.36 (p=0.031) and 1.38 (p=0.041) in RSP. CONCLUSIONS: Presence of obstructive airflow limitation indicative of COPD or RSP were associated with increased all-cause mortality, however only independently when using the LLN definition.
Authors: Marco Guazzi; Jonathan Myers; Marco Vicenzi; Daniel Bensimhon; Paul Chase; Sherry Pinkstaff; Ross Arena Journal: Am Heart J Date: 2010-11 Impact factor: 4.749
Authors: J Roca; F Burgos; J Sunyer; M Saez; S Chinn; J M Antó; R Rodríguez-Roisin; P H Quanjer; D Nowak; P Burney Journal: Eur Respir J Date: 1998-06 Impact factor: 16.671
Authors: Wouter van Dijk; Wan Tan; Pei Li; Best Guo; Summer Li; Andrea Benedetti; Jean Bourbeau Journal: Ann Fam Med Date: 2015 Jan-Feb Impact factor: 5.166
Authors: Tamara B Horwich; Gregg C Fonarow; Michele A Hamilton; W Robb MacLellan; Jeff Borenstein Journal: J Am Coll Cardiol Date: 2002-06-05 Impact factor: 24.094
Authors: M P Swanney; G Ruppel; P L Enright; O F Pedersen; R O Crapo; M R Miller; R L Jensen; E Falaschetti; J P Schouten; J L Hankinson; J Stocks; P H Quanjer Journal: Thorax Date: 2008-09-11 Impact factor: 9.139
Authors: Hwa Mu Lee; Yanglu Zhao; Michael A Liu; David Yanez; Mercedes Carnethon; R Graham Barr; Nathan D Wong Journal: Clin Cardiol Date: 2018-07-17 Impact factor: 2.882
Authors: Nickson Melo De Morais; Micássio Fernandes De Andrade; Valéria Duarte De Almeida; Lara Candice Costa De Morais Leonez; Cléber Mesquita De Andrade; Christiane Medeiros Bezerra; Ellany Gurgel Cosme Do Nascimento; José Veríssimo Fernandes; Thales Allyrio Araújo De Medeiros Fernandes Journal: Biomed Rep Date: 2022-09-15
Authors: E Bossone; M Arcopinto; M Iacoviello; V Triggiani; F Cacciatore; C Maiello; G Limongelli; D Masarone; F Perticone; A Sciacqua; P Perrone-Filardi; A Mancini; M Volterrani; O Vriz; R Castello; A Passantino; M Campo; P A Modesti; A De Giorgi; I Monte; A Puzzo; A Ballotta; L Caliendo; R D'Assante; A M Marra; A Salzano; T Suzuki; A Cittadini Journal: Intern Emerg Med Date: 2018-04-04 Impact factor: 3.397
Authors: Claire A Lawson; Mamas A Mamas; Peter W Jones; Lucy Teece; Gerry McCann; Kamlesh Khunti; Umesh T Kadam Journal: JAMA Netw Open Date: 2018-12-07